Welcome to our dedicated page for Cell Medx news (Ticker: CMXC), a resource for investors and traders seeking the latest updates and insights on Cell Medx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cell Medx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cell Medx's position in the market.
StimCell Energetics Inc. (OTC PINK:CMXC), formerly Cell MedX Corp., announced major corporate changes including a name change and a 1:15 reverse stock split. The company's authorized capital decreased from 7.5 billion to 500 million shares, with outstanding shares reducing from 297,236,373 to approximately 19,815,758. Starting November 5, 2024, the stock will trade as 'CMXCD' for 20 business days before seeking a new symbol. The biotech company, focusing on cellular energy for anti-aging and wellness, also launched a new website at www.StimCell.com.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Cell Medx (CMXC)?
